Accordingly, the clinical integration of less specific tumor biomarkers such as CA-125 in pediatric oncology remains uncertain, and their use should be restricted to a multimodal diagnostic framework that incorporates clinical assessment, imaging findings, and established pediatric tumor-specific biomarkers. This evidence concerns the gene MUC16 and neoplasm.